Top Ten most popular articles on this week

pharmafile | October 11, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

It’s the end of the week and time for a rundown of our top most popular articles on Pharmafile these past 7 days. This week saw numerous FDA approvals as well as a few research collaborations that could see new treatments being fully developed over the coming years. Here they are:

10. Novartis’ legelizumab outperforms Roche’s Xolair in chronic urticaria clearance

Novartis has pulled back the curtain on new Phase 2b data for its IgE/FceR1 pathway-blocking drug ligelizumab, showing that the therapy outperformed Roche’s Xolair (omalizumab) in key metrics as a treatment for chronic spontaneous urticaria in patients whose symptoms are inadequately controlled by H1-antihistamines.

9. FDA approves single-use auto-injector form of IL-5 inhibitor Fasenra

AstraZeneca is celebrating as the FDA announced the approval of its IL-5 inhibitor Fasenra  (benralizumab) in a pre-filled, single-use auto-injector form, known as the Fasenra Pen.

8. FDA approves second PrEP drug to prevent HIV infection

The US FDA has approved Gilead’s Descovy (emtricitabine/tenofovir alafenamide) as a second pre-exposure prophylaxis (PrEP) drug in at-risk adults and adolescents weighing at least 75lbs for the prevention of HIV infection.

7. UK watchdog finds drug firms colluded to hike essential NHS medication by 1,800%

The UK’s Competition and Markets Authority (CMA) has provisionally found that three drug firms signed an illegal agreement which led to huge price hikes for an essential medicine used by the NHS.

6. Bayer UK unveils new Artificial Intelligence ‘LifeHub’

Bayer has launched LifeHub UK as part of a network of global innovation hubs designed to accelerate and optimise disease detection and data-driven drug discovery by developing Artificial Intelligence-enabled imaging solutions.

5. Johnson & Johnson ordered to pay man $8bn over breast growth

US pharma giant Johnson & Johnson has been ordered to pay $8 billion in punitive damages to a man over claims he was not warned than antipsychotic drug Risperdal could lead to breast growth.

4. Pfizer to develop Akcea/Ionis’ Antisense Drug for up to $1.5bn

Pfizer and Akcea Therapeutics have entered into an exclusive worldwide licensing agreement for Akcea’s phase 2 cardiovascular and metabolic candidate AKCEA-ANGPTL3- LRx in a deal that could generate over $1.5 billion for Akcea and its parent company Ionis Pharmaceuticals.

3. FDA approves Novartis’ Beovu injection for wet age-related macular degeneration

Novartis has secured FDA approval for its Beovu (brolucizumab) injection in the treatment of wet age-related macular degeneration (AMD), it has emerged.

2. Johnson & Johnson win FDA Breakthrough status for cancer drug Zejula

The US FDA has granted breakthrough therapy designation for Johnson & Johnson’s Zejula (niraparib) for the treatment of metastic prostate cancer, who have previously received hormone treatments and chemotherapy and who also have mutations in the BRCA1 and BRCA2 genes.

1. Novo Nordisk enters into haemophilia gene therapy collaboration

Novo Nordisk and bluebird bio have announced they have entered into a three-year research collaboration to jointly develop next-generation in vivo genome editing treatments for genetic diseases, including haemophilia.

Related Content

No items found

Latest content